Molecular biomarkers for Alzheimer’s disease (AD) can support detection and improved care for patients, but novel candidates require verification. We previously reported a 12-micro RNA (miRNA) blood-based signature using next-generation sequencing (NGS) of 54 AD cases and 22 controls.
from Dementia Big http://ift.tt/1ncyy1A
via Stopping Dementia
from WordPress http://ift.tt/1K0DkK3
via alcoholic dementia
http://ift.tt/1WzKs20
No comments:
Post a Comment